Oruka Therapeutics(ORKA.US)

ProImmune Introduces Mastering Immunity 2026 - Shanghai Symposium to Address Key Immunogenicity Challenges

ProImmune Ltd has announced the Mastering Immunity 2026 symposium, set for April 13-14, 2026, at the Oriental Riverside Hotel in Shanghai. This inaugural event will focus on immunogenicity challenges in drug development, featuring global leaders in biotherapeutics and regulatory authorities. The symposium aims to provide practical guidance for managing immunogenicity risks, which can significantly impact the success of drug programs. Notable speakers include experts from the FDA, Pfizer, and Roche. The event is positioned as essential for those involved in the biopharmaceutical industry in China.

Health Rounds: How obesity leads to uncontrolled inflammation discovered

Researchers have discovered the pathway linking obesity to uncontrolled inflammation, which can lead to serious health issues like diabetes and liver disease. The study highlights the role of the NLRP3 protein complex and the enzyme SAMHD1 in this process. Additionally, new research suggests that messenger RNA could be used to improve embryo attachment in the uterus, potentially offering new treatments for infertility. This involves using lipid nanoparticles to deliver genetic material that enhances the endometrium's ability to support embryo implantation.

Industry ETFs in the U.S. stock market opened almost entirely in decline, with the Biotechnology Index ETF, Consumer Discretionary ETF, and Global Technology Stocks Index ETF down by as much as 2.29%. The Internet Stocks Index ETF, Technology Sector ETF, and Semiconductor ETF fell by as much as 1.82%, while the Energy Sector ETF rose by 0.55%

Pre-market hot trades in US stocks: Galaxy Payroll pre-market down 15.61%; United Microelectronics pre-market up 14.09%

Galaxy Payroll pre-market down 15.61%; United Microelectronics pre-market up 14.09%; INVO Fertility pre-market up 405.91%; Icon Energy pre-market up 140.21%; RAPT Therapeutics pre-market up 63.42%

Ascletis chooses ASC37, a once-monthly subcutaneously administered peptide agonist, with 17-day half-life, for clinical development.

ASC37 has shown to have an average observed half-life of around 17 days in head-to-head non-human primate studies, which is 7 times longer than retatrutide. This indicates its potential for once-monthly subcutaneous dosing in humans. Additionally, ASC37 exhibited approximately 5-, 4-, and 4-fold greater in vitro activity compared to other substances.